Wellfully (ASX:WFL) - CEO, Paul Peros
CEO, Paul Peros
Source: Cosmetics Design Asia
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Wellness group OBJ has announced it had only secured offers for 37 per cent of new shares on offer during a recent capital raise
  • OBJ announced last month it was aiming to raise between $3 million and $4.5 million via an entitlement offer and placement
  • Shareholders were offered one new share for every three already held under the offer, with the new shares prices at 10 cents each
  • In the end, OBJ received applications for over 11 million new shares, raising $1.12 million via the offer
  • Shares in OBJ have been suspended since November 2019, and last traded for 1.2 cents each

Wellness group OBJ (OBJ) isn’t looking too well, after only securing offers for 37 per cent of new shares offered during a recent capital raise.

OBJ first announced the non-renounceable entitlement offer on July 10, as well as a proposed placement.

Under the entitlement offer, shareholders were offered one new share for every three already held, with the new shares priced at 10 cents each.

While under the placement, 15 million shares would be sold at the same price, but to sophisticated and professional investors.

When the two equity raises were combined the company was hoping to raise up between $3 million and $4.5 million.

The company today revealed it had closed the entitlement offer with a shortfall, as only 37 per cent of eligible shareholders subscribed for new shares.

This means OBJ will walk away with $1.12 million, well below the minimum $3 million target.

The company’s board of directors and Lead Manager, CPS Capital Group, will now place the shortfall shares to professional and sophisticated investors.

There are over 18 million new shares still on offer and they will be placed at the board and CPS Capital’s discretion.

Meantime, shares in OBJ have been suspended since November 2019, and last traded for 1.2 cents each.

OBJ by the numbers
More From The Market Online

This stock provides Oz’s only HIV self-test kit – and it’s bullish on the budget

Atomo Diagnostics is the only company in Australia that provides TGA-approved HIV self-test kits. It says…

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial…
The Market Online Video

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug…

Optiscan agreement with Mayo Clinic aims to expedite robotic surgery

Optiscan Imaging is parterning with Mayo Clinic to develop a digital confocal laser endomicroscopic imaging system